Related Experiment Video
Updated: Jun 21, 2026

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
Published on: May 31, 2016
Arterial accelerated aging in dialysis patients: the clinical impact of vascular calcification
Diego Brancaccio1, Antonio Bellasi, Mario Cozzolino
1Department of Nephrology, San Paolo Hospital, University of Milan, Italy. diego.brancaccio@ tiscalinet.it
Insights
Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) involves abnormal bone and mineral metabolism, leading to vascular calcification (VC) and increased mortality. Current strategies focus on managing calcium, phosphate, and parathyroid hormone levels to prevent VC progression.
Area of Science:
- Nephrology
- Endocrinology
- Pathology
Background:
- Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) is a complex condition affecting mineral and bone metabolism in CKD patients.
- CKD-MBD is characterized by serum calcium and phosphate imbalances, altered bone turnover, and vascular calcification (VC).
- VC in uremic patients shares similarities with bone mineralization, suggesting a biological link to mineral derangements and increased mortality.
Purpose of the Study:
- To review the current understanding of vascular calcification (VC) in Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD).
- To summarize evidence-based strategies for preventing and treating VC in CKD patients.
- To highlight the link between VC and increased mortality in CKD-MBD.
Main Methods:
- Review of current literature on CKD-MBD and vascular calcification.
- Analysis of the biological processes underlying VC in CKD.
- Synthesis of evidence supporting current treatment modalities for VC.
Main Results:
- Vascular calcification begins in early CKD stages and is prevalent in advanced stages (CKD-3, -4, -5).
- The presence and extent of VC are associated with poor prognosis in CKD patients.
- VC is an active biological process analogous to bone mineralization.
Conclusions:
- Effective management of calcium, phosphate, and parathyroid hormone is crucial in CKD-MBD.
- Utilizing calcium-free phosphate binders and vitamin D analogs are key therapeutic strategies.
- These interventions aim to improve quality of life and reduce mortality in CKD patients by mitigating VC.
Abstract:
Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) is a systemic disorder of mineral and bone metabolism that occurs in Chronic Kidney Disease (CKD). In addition to abnormalities in serum calcium (Ca) and phosphate (P) profile, CKD-MBD is characterized by abnormalities of bone turnover, mineralization, volume and growth as well as vascular calcification (VC). Indeed, the co-localization of bone markers such as Osteopontin, Alkaline Phosphatase and Osteocalcin along with osteoblast-like cells in the contest of the arterial wall of uremic patients, indicate that VC is an active biological process with peculiar analogies with bone mineralization. Thus, VC represents a plausible link between Ca and P derangements and the increased mortality associated with CKD-MBD. The process of VC starts in early stages of CKD and patients with CKD-3, -4 and -5 not undergoing haemodialysis may present a significant burden of calcification in the coronaries. Considering that presence and extent of VC in CKD portend poor prognosis, many efforts have been made to shed light on this complicated phenomenon to prevent VC deposition and progression. Indeed, careful control of calcium load, serum P and parathyroid hormone along with the use of calcium-free P binders and vitamin D analogs represent our current armamentarium to improve quality of life and reduce mortality in CKD. We herein summarize the current understanding and evidence supporting strategies available for VC treatment.
Related Concept Videos
Hemodialysis I: Introduction
Chronic Kidney Disease II: Clinical Manifestations
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Peripheral Artery Disease I: Introduction
Hemodialysis II: Procedure and Complications
Hemodialysis III: Nursing Management

